The German CML Alliance is a nationwide initiative which works to create wider and easier access to innovative treatment.
Each year approximately 1200 people are diagnosed with chronic myeloid leukemia (CML). Thanks to the development of a new class of medicines around the turn of the millennium, the majority of CML patients have a normal life expectancy and quality of life. The resulting demographic change opens up new questions and places new therapy goals in the forefront.
Innovative ideas are not the only force driving advances in treatment: long-term, concerted cooperation on the part of physicians, clinic and hospital staff as well as patients is essential. In acknowledgement of this fact, the CML Alliance provides practical support for the conducting of clinical trials in several ways. The CML Alliance offers information and training events, fosters investigator networks, provides access to current study information, supports efforts to standardize laboratory diagnostics and promotes the inclusion of the patient perspective in clinical research projects.
The CML Alliance brings together and provides a platform for physicians and study personnel from all medical settings—i.e. private practice, medical care centers, municipal and private hospitals and university medical centers—laboratory diagnosticians and patient advocates in an effort to improve the infrastructure for clinical research in Germany.
The CML Alliance is coordinated from a project office at the Jena University Hospital. Visit the CML Alliance online at www.cml-allianz.de